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ABSTRACT 
 
 
  
 E3 ubiquitin ligases, such as SCF
Grr1
, are enzymes that add ubiquitin chains to proteins 
targeting them to the proteasome for degradation. Deubiquitinating enzymes (DUBs) can 
counteract this activity by removing ubiquitin chains and thus rescue proteins from degradation. 
Our goal was to develop genetic and biochemical screening approaches to identify DUB 
substrates, and thus learn more about DUBs that may contribute to human disease.  Our data 
suggests that the yeast DUBs Ubp3 and Ubp12 affect the stability of the Grr1 targets Cln2, Cln3, 
and Gic2. 
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BACKGROUND 
 
 
 
The Cell Cycle 
 
In order for eukaryotic cells to successfully replicate and divide, they go through a 
unidirectional process called the cell cycle (Figure-1). The cell cycle consists of four phases: G1, 
S, G2, and M. Together, G1, S, and G2 phases are called interphase because it is during this time 
that preparations for cell division occur. During G1 phase, cells grow and commit to entering the 
cell cycle. G1 is followed by the S phase (DNA synthesis phase), when DNA replication occurs, 
then enter G2, a second growth phase when the duplicated chromosomes are checked to make 
sure they were copied properly. Finally, during M phase, or mitosis, duplicated chromosomes are 
segregated to daughter cells and cell division (cytokinesis) occurs (Cooper, 2000). Mitosis can be 
further subdivided into prophase, prometaphase, metaphase, anaphase, telophase, and 
cytokinesis. During these stages, DNA condenses and the nuclear membrane breaks apart, 
chromosomes line up at the equator of the spindles, spindle fibers pull sister chromatids to 
opposite poles of the cell, and the cell pinches in half to form two new cells while the nucleus 
reforms around the DNA (Carter, 2010).  
 
Figure-1: The Cell Cycle. (Anderson, 2010) 
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Cell Cycle Checkpoints 
 
A cell must complete the full cell cycle in order to divide properly. Therefore, in order to 
make sure that a cell is prepared to divide, there are various checkpoints throughout the cycle to 
ensure that no errors were made before the cell progresses into the next phase. In mammalian 
cells, checkpoints control the activity of cyclin-dependent kinases (Cdks), whose activities are 
required for the cell cycle to proceed (Johnson & Walker, 1999). For example, a G2 phase 
checkpoint is activated if DNA damage is found after S phase. If this occurs, the cell cycle is 
halted through the inhibition of Cdk1-cyclin B complex, which prevents the cell from entering M 
phase (Lindqvist, 2009). If the damage can be fixed, then it will be, and the cell will segregate its 
chromosomes and divide. But, if the damage is unable to be repaired, then the cell will arrest or 
die, in a process known as apoptosis.  
Cancer is a disease caused by uncontrolled cell division. Therefore, misregulation of the 
cell cycle can lead to cancer (Cohen & Tcherpakov, 2010; Cristina, 2011). If checkpoints are not 
functioning properly, then a cell with DNA mutations may pass through the cycle and divide, 
potentially leading to uncontrolled cell division and tumor formation. The most commonly 
mutated protein in cancer cells is the tumor suppressor p53, which normally functions to arrest 
cells in G1 and/or G2 phase following DNA damage (Nigro, 1989). If p53 is mutated, then cells 
will continue to divide even though DNA damage is present, and this can lead to the 
development of a tumor. Therefore, understanding the proteins and mechanisms that control the 
cell cycle will aid in our understanding of how cancer develops, and allow us to develop better 
ways to treat the disease. 
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The Importance of Regulating Protein Levels Throughout the Cell Cycle 
 
Fluctuations in cell cycle protein levels drive cell cycle progression, and this occurs 
through a combination of the cyclical transcription of cell cycle genes and degradation of the 
corresponding proteins. A large fraction of the genome is expressed in this cyclical way; for 
example, one-sixth of the yeast genome is transcribed in a cell cycle-dependent manner 
(Spellman, et al., 1998). The degradation of previously expressed proteins, and the expression of 
new proteins, helps ensure that the cell continues the cycle and does not go backwards (King & 
Cidlowski, 1998). Cell cycle proteins that are transcribed at high levels at the beginning of a 
specific phase are often degraded rapidly near the end of that phase. For example, cyclin E is 
rapidly synthesized in late G1, and rapidly degraded in mid-S (Figure-2). This regulation 
ensures that DNA does not get re-replicated before the next cell cycle, which can lead to 
mutations in the genome. Therefore, the properly timed expression and degradation of these cell 
cycle control proteins is essential for a complete and accurate cell cycle. 
 
 
 
 
 
 
 
 
 
 
 
Figure-2: Fluctuation in Cyclin Levels Throughout  
the Cell Cycle. (Verschuren, 2004) 
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Protein Degradation 
 
 Degradation of cellular proteins occurs by two separate mechanisms: non-specific 
degradation and regulated degradation. Non-specific degradation occurs by autophagy in the 
mammalian lysosome or yeast vacuole, and leads to the bulk turnover of cytoplasmic material. In 
this process, cellular components are engulfed non-selectively in vesicles called “autophagic 
bodies” and then brought to the vacuole where the vesicle is broken down then all the contents 
inside are degraded to allow for cellular components to be recycled (Kim & Klionsky, 2000). 
Autophagy typically occurs when the cell is starved and needs to obtain more nutrients.  
 Regulated degradation occurs through the ubiquitin-proteasome pathway, in which 
specific proteins are marked for degradation by the addition of ubiquitin chains that target them 
to the proteasome. Many cell cycle proteins are regulated through this ubiquitin-proteasome 
degradation pathway (Figure-3). The energy of ATP is used to form a thiol ester bond between 
ubiquitin and an activating enzyme E1 (Ventii & Wilkinson, 2008). The activated ubiquitin is 
then attached to one of many E2s (ubiquitin-conjugating enzymes), and then transferred to the 
appropriate protein target by an E3 ubiquitin-ligase forming an isopeptide bond (Hershko & 
Ciechanover, 1998).  
 
 
 
Figure-3: Proteolysis Using 
Ubiquitin.  (Nakayama 
2006) 
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The E3 ubiquitin ligase continues to add ubiquitins to the target using the 7 lysine 
residues of ubiquitin as attachment sites to form ubiquitin chains. Therefore, multiple chain 
structures can be made, and different chain linkages determine different target outcomes 
(Figure-4). Only K48- and K11-linked chains (as listed in example B in the figure), with a 
minimum of four ubiquitins, signals the target to the 26S proteasome where it is degraded into 
short peptides (Coux, et al., 1996; Nijman, et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4: Ubiquitin Chain Signals. (Ventii & Wilkinson, 2008) 
 
 
E3 Ubiquitin Ligases 
 
The functions of most E3s that exist in eukaryotic cells are unknown. There are two 
families of E3s, those containing HECT domains and those with RING finger domains (Chen, et 
al., 2006).  RING ligases act by bringing together E2-ubiquitin conjugates and the protein target 
to catalyze the transfer of ubiquitin, while HECT E3s become conjugated to the ubiquitin before 
transferring to the target. RING domain E3s can be further subdivided into monomeric RINGs 
and multi-subunit RINGs, which function as large protein complexes. The two best-characterized 
multi-subunit RING E3s are the Anaphase Promoting Complex/Cyclosome (APC/C) and Skp1-
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Cullin-F-box Complexes (SCF) (Petroski & Deshaies, 2005) (Figure-3). The APC is mainly 
active during mitosis and G1 phases. Its essential functions are to degrade mitotic cyclins and 
ubiquitinate securin, an anaphase inhibitor, allowing for sister chromatid separation. SCF 
complexes are present throughout the cell cycle, evolutionary conserved, and have more diverse 
functions than the APC. As the name suggests, SCF complexes consist of several components: 
the adaptor protein Skp1, a structural cullin subunit (Cul1 in mammals, Cdc53 in yeast), and the 
RING finger protein Rbx1 (Deshaies, 1999). In addition, each SCF E3 contains one of a large 
family of F-box proteins that bind to specific substrates, usually in a phosphorylation-dependent 
manner. One of the best-characterized roles of SCF E3s is to ubiquitinate cell cycle regulatory 
proteins, such as cyclins and cdk inhibitors, through the specific interaction of the F-box protein 
with the phosphorylated targets (Vodermaier, 2004). 
 
Ubiquitin Ligases in Budding Yeast 
 
The budding yeast, Saccharomyces cerevisiae, is used as a model organism to study 
complex eukaryotic processes such as cell cycle regulation for several reasons. Its genome is 
translatable to humans (Bentley & Carr, 1997; Freire, et al., 1998; Sanchez, et al., 1997), but the 
yeast genome is less complex than the human genome, consisting of 16 linear chromosomes and 
approximately 6000 genes (Zagulski, et al., 1998). In addition, the cell cycle phases can be 
visibly observed in yeast based on cell shape, making cell cycle progression easy to monitor. 
Yeast is also easy to maintain, easy to genetically manipulate, and have a generation time of only 
90 minutes (Perego, et al., 2000). 
 The SCF ubiquitin ligase containing the F-box protein Grr1 (SCF
Grr1
) is one of the best-
characterized E3s in budding yeast. Cells lacking GRR1 show several abnormalities, such as 
elongated cell morphology, loss of glucose repression, and filamentous defects (Blacketer, et al., 
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1995; Flick & Johnston, 1991; Loeb, et al., 1999). Moreover, SCF
Grr1
 plays an important role in 
regulating the cell cycle because it targets all three G1 cyclins: Cln1, Cln2, and Cln3 (Barral, et 
al., 1995; Benanti et al, submitted) (Figure-5). 
 
 
 
 
 
 
 
 
 
Figure-5: Ubiquitination of Cln1 and Cln2 Through the  
Grr1 SCF Complex. (Johnston, 1999) 
 
 
Other known Grr1 targets include the Cdc42 GTPase-associated protein Gic2 
(Jaquenoud, et al., 1998), which is involved in bud initiation and polarizing actin cytoskeleton, 
Hof1, which helps to create a functional actomyosin ring early in mitosis and complete 
cytokinesis (Blondel, et al., 2005), and the glycolysis regulators Tye7 and Pfk27 (Benanti, et al., 
2007). Since the pathways regulating the degradation of Grr1 targets are well-understood, these 
proteins serve as good model substrates to study regulation of the ubiquitin-proteasome system. 
 
Deubiquitinating Enzymes  
 
 The action of ubiquitin ligases can be further regulated by deubiquitinating enzymes 
(DUBs) that function to remove or remodel ubiquitin chains (Ventii & Wilkinson, 2008). 
Additionally, it is important to learn about the function of DUBs because they are often found 
mutated in many diseases, including cancer (Hussain, et al., 2009). DUBs have several 
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regulatory roles in the ubiquitin pathways (Figure-6). For instance, they can remove ubiquitin 
chains from proteins saving them from degradation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: Function of Deubiquitinating Enzymes  
in Proteolysis. (Ventii & Wilkinson, 2008) 
 
Interestingly, monoubiquitin is more easily removed by DUBs in vitro than polyubiquitin chains 
of four or more, especially those ubiquitins that are linked by lysine 48 (Schaefer & Morgan, 
2011), suggesting that proteins with shorter ubiquitin chains are more likely to be rescued from 
degradation in the proteasome.  
DUBs are classified as either cysteine protease DUBs or zinc metalloproteases DUBs 
(JAMM domain-“JAB1/MPN/MOV34”) (Nijman, et al., 2005). The cysteine protease DUBs can 
be further subdivided into: ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases 
(UCHs), octubain proteases (OTUs), and Machado-Joseph disease proteases (MJDs) (Nijman, et 
al., 2005). The USPs are the most common type of cysteine proteases, comprising 56 of 79 
human DUBs, and 16 of 20 yeast DUBs (called UBPs) (Komander, et al., 2009; Schaefer & 
Morgan, 2011). 
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Genetic screens suggest that DUBs perform several functions in the cell. For example, 
they are involved in synapse function, RNA interference, signaling cascades, gene expression, 
DNA repair, apoptosis, kinase activation, and other functions (Nijman, et al., 2005; 
Ramakrishna, et al., 2010). In vitro, DUBs have been shown to process ubiquitin precursor 
proteins, edit ubiquitin modifications by rearranging ubiquitin chains, remove chains from 
posttranslationally modified proteins, and rescue ubiquitin conjugates (Komander, et al., 2009). 
Much less is known about DUB functions in vivo. DUBs are often associated with other proteins 
such as substrates, adaptors, and scaffolds, which helps determine their specificity (Sowa, et al., 
2009; Kouranti, et al., 2010), however the specific proteins that most DUBs deubiquitinate are 
largely unknown. Therefore, I have undertaken a study of the 17 highly conserved DUBs in 
yeast, to develop an approach that can be used to identify in vivo targets. 
 
PROJECT PURPOSE 
 
 
Although a few in vivo substrates of DUBs have been identified (Amerik, et al., 2000; 
Amerik & Hochstrasser, 2004; Nijman, et al., 2005; Hanna, et al., 2006; Komander, et al., 2009), 
the identities of proteins that yeast DUBs individually target for deubiquitination in vivo are 
largely unknown. It is known, however, that substrate-specific DUBs exist. For example, in 
human cells USP28 regulates the degradation of the Myc oncoprotein (Popov, et al., 2007). 
Despite the established connections between DUBs and human disease, no approach has been 
developed to systematically identify in vivo targets of DUBs. My goal is to develop an approach 
to identify DUB substrates, and thus learn more about DUBs that contribute to human disease. 
I hypothesize that overexpression of DUBs that act on ubiquitin-proteasome pathway 
targets will lead to target protein stabilization, and therefore increased levels of proteasome 
targets. To test this hypothesis, I will examine the regulation of several Grr1 substrates by yeast 
DUBs using biochemical and genetic approaches. The biochemical approach will consist of 
overexpressing each of the known 17 DUBs in yeast, and identifying those that lead to an 
increase in the stability of any Grr1 targets. This will be done by transforming plasmids encoding 
each of the 17 DUBs into 2 Grr1 target reporter strains, each expressing three epitope-tagged 
Grr1 targets. The strains will be grown in galactose to induce transcription and overexpression of 
the DUBs, and Western blots will be used to analyze the cellular levels of each of the Grr1 target 
proteins for changes in expression. It is predicted that DUBs that can deubiquitinate Grr1 targets 
will display an increase in those target’s expression upon overexpression in vivo.  
As an alternate approach, I will look for genetic interactions between DUBs and GRR1. 
Overexpression of GRR1 leads to slow growth, presumably from accelerated degradation of Grr1 
substrates. I will screen for DUBs that reverse this phenotype, by overexpressing both the DUBs 
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and Grr1 in vivo in yeast, and then determining whether any of the DUBs rescue the slow-growth 
phenotype that is observed following overexpression of Grr1 alone. This will be accomplished 
by creating strains carrying both a Grr1 overexpression plasmid and one of each of the 17 DUBs. 
These strains will be serially diluted onto dextrose plates, upon which both Grr1 and DUB 
expression are silenced, and galactose plates, which will induce the expression of both Grr1 and 
the DUB. I will then determine if any of the DUBs are able to rescue the slow growing cells. It is 
predicted that only DUBs that deubiquitinate Grr1 targets will show increased growth on the 
galactose plates. Together, these approaches will tell us whether we can identify DUB targets in 
vivo by overexpressing individual DUBs. If successful, this approach can be adapted in the future 
to perform genomic screens to identify all yeast and human DUB targets. 
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METHODS 
 
Yeast Grr1 Target Reporter Strains 
 
 Two yeast strains were created that each had 3 Grr1 targets tagged with different epitope 
tags, to allow the Western blotting of several different proteins at the same time. To create strain 
YPS2-4, CLN2 was tagged with 3HA-KanMX, CLN3 tagged with 13MYC-HIS3, and PFK27 
was tagged with 3FLAG-Hyg.  To create strain YPS5-3, GIC2 was tagged with 3HA-KanMX, 
HOF1 was tagged with 13MYC-HIS3, and TYE7 was tagged with 3FLAG-Hyg. 
 
Polymerase Chain Reactions  
 Epitope tag sequences, along with genes encoding selectable markers, were amplified via 
Polymerase Chain Reaction (PCR) using plasmid DNA templates (pFA6a-3HA-KanMX, 
p3FLAG-Hygro, pFA6a-13MYC-HIS3MX) and primers that contained sequences to both 
amplify the appropriate tag and to allow for homologous recombination of the tagging cassette at 
the desired genomic locus. A sample of each PCR product was then run in a 1% agarose gel with 
1 g/mL ethidium bromide at 140V for 30 minutes, and observed under UV light to make sure 
the product had been amplified. Once confirmed, the PCR product was ethanol precipitated, and 
placed in at -20ºC for storage. 
 
High-efficiency Transformation 
  
 Prior to transformation, a culture of the parent yeast strain was innoculated in YM-1/2% 
dextrose, and grown until reaching an OD of 0.5-1.0. The culture was then spun down, washed, 
and resuspended in Lithium Acetate mix (100 mM lithium acetate, 10 mM Tris-Cl, 1 mM 
EDTA, pH8). Next, 100 L of yeast suspension was aliquoted into tubes containing 10 l of the 
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PCR product, 100 g of Salmon Sperm DNA, and 0.7 mL of PEG mix (40% PEG, 100 mM 
lithium acetate, 10 mM Tris-Cl, 1 mM EDTA, pH8). The samples were incubated for at least 30 
minutes at 30ºC. The transformation tubes were then heat shocked for 15 minutes at 42ºC, 
centrifuged for 30 seconds, and resuspended in 300 L of YM1/2% dextrose.  Finally, the cells 
were spread on the appropriate selection plates (G418, Hygromycin, -Histidine) and grown at 
30ºC. 
 
Zymo Prep Colony PCR 
  
 Single colonies that grew on selective plates were transferred using a toothpick onto new 
selection plates, and checked by PCR to confirm that the tag had recombined into the correct 
location in the genome. First, genomic DNA was prepared by aliquotting 50 L of diluted 
zymolyase enzyme mix into PCR tubes and resuspending single colonies in the tubes. They were 
incubated for 30 minutes at 37ºC, and then for 10 minutes at 95ºC.  The DNA was then aliquoted 
into new PCR tubes along with the PCR reaction mix, including primers specific to each gene. 
The PCR program was run, and the product was checked by electrophoresis to see if a PCR 
product resulted, indicating that the epitope tag sequence had recombined into the correct 
location. 
  
Yeast GST Fusion Plasmid and Yeast MORF Collection Plasmids 
 Two different plasmid collections, GST and MORF, were purchased from Open 
Biosystems. Plasmids in each set include a galactose-inducible promoter that drives expression 
of each epitope-tagged protein.  I utilized 11 GST plasmids and 6 MORF plasmids, each 
expressing a different DUB gene. All plasmids were confirmed by sequencing before use. The 
main components of the plasmids and how they are different are illustrated below (Figure-7).  
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Figure-7: Diagram of GST and MORF Plasmids. The plasmids are similar in that 
they both include a URA3 marker, a GAL1 promoter, and contain a 2 micron origin of replication, 
meaning that they replicate at a high copy number. They differ because the GST plasmids include 
both GST and His tags, while the MORF plasmids have HA and Protein A tags. 
 
Plasmid Transformations 
 Various plasmids were transformed into YPS2-4 and YPS5-3 in order to induce DUB 
overexpression. Cells were grown to mid-log phase in YM1/2% dextrose media, aliquoted into 
tubes, centrifuged, and the supernatant was decanted. Next, salmon sperm DNA and the plasmids 
were added. Then PLATE solution (40% PEG, 0.1 M lithium acetate 10 mM Tris-HCl, pH7.5, 1 
mM EDTA) and DMSO were added, and the transformations were incubated at room 
temperature for at least 30 minutes. They were then heat shocked, centrifuged, and resuspended 
in TE. Finally, they were plated onto selective plates (-Uracil for DUB plasmids, -Leucine for 
GRR1 plasmid). 
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Galactose Inductions 
 DUB plasmids in YPS2-4 and YPS5-3 were all under the GAL1 promoter, therefore 
transcription was induced when galactose was added. Overnight cultures were diluted into 2 
identical aliquots of complete medium lacking uracil (to select for cells containing the plasmid) 
plus 2% raffinose, and grown until cells had doubled. Then, galactose was added to one culture 
to a final concentration of 2%. The cultures were grown for another 2 hours in 30ºC, and then 6 
optical densities (ODs) were collected from each sample. The cells were collected by 
centrifugation at 4ºC, washed in H2O, centrifuged again, and pellets were stored at -80ºC. 
 
Western Blotting 
 Equivalent pellets of cells were lysed in pre-heated SDS sample buffer (50 mM Tris 
pH7.5, 5 mM EDTA, 5% SDS, 10% glycerol, 0.5% -mercaptoethanol, bromophenol blue, 1 
g/mL leupeptin, 1 g/mL bestatin, 1 mM benzamidine, 1 g/mL pepstatin A, 17 g/mL PMSF, 
5 mM sodium fluoride, 80 mM -glycerophosphate, and 1 mM sodium orthovanadate), and 
incubated at 95ºC for 5 minutes. Glass beads were then added to samples, bead-beat for 3 
minutes in a MiniBeadBeater-96 (Biospec), and then centrifuged for 25 minutes. Extracts were 
then electrophoresed by SDS-PAGE for 2 hours at 140V, transferred to a nitrocellulose 
membrane for 2 hours at 0.45 Amps, and western blotted with antibodies against MYC (Clone 
9E10, Covance), HA (Clone 16B12), FLAG (Clone M2, Sigma), GST (Clone 4C10, Covance), 
and Cdc28 (sc-6709, Santa Cruz Biotechnology). 
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Cycloheximide-Chase Assays 
 The same protocol as Galactose Induction was used, except after induction, 50 g/mL 
cycloheximide was added to cells. Cell pellets from equivalent ODs of cells were collected at 15 
minute time points over the course of 1 hour and samples analyzed by Western blotting. 
 
GRR1 Plasmid Construction 
 GRR1 was cloned into a LEU2-containing expression vector so that it could be 
introduced into cells also carrying URA3-expressing DUB plasmids. To accomplish this, GRR1 
was amplified from genomic DNA by PCR and cloned into the pRS325-GAL1p vector. The 
cloned plasmid is shown below (Figure-8). 
 
 
 
Figure-8: GRR1 Plasmid Cloning. The plasmid has a LEU2 marker, an HA tag, a GAL1 
promoter, and contains a 2 micron origin of replication, meaning that it replicates at a high copy 
number.  
 
Serial Dilution (Spot) Assay 
Yeast cultures were innoculated in selective media (C-Uracil, C-Leucine, C-Leucine-
Uracil)/2% dextrose, and grown overnight until cells had doubled.  Equal aliquots (0.4 ODs) 
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were centrifuged down, washed twice in media without sugar, and 5-fold serial dilutions were 
then plated onto dextrose and galactose plates. All plates were incubated at 30°C until control 
colonies were of equivalent size. 
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RESULTS 
 
The purpose of this project was to develop biochemical and genetic approaches to 
identify DUB substrates, to learn more about DUBs that may contribute to human disease. 
 
Initial DUB Tests 
Before examining the effect of DUB overexpression on substrates, I sought to confirm 
that the plasmids expressed each protein of interest, and to screen for potential growth inhibition 
resulting from overexpression of each DUB. I first sequenced and confirmed 11 GST plasmids 
and 6 MORF plasmids, each containing 1 of 17 yeast DUB genes expressed from the GAL1 
promoter. Three DUBS (UBP8, UBP14, UBP15) were not included in either the GST or MORF 
collection and were not included in my analysis. The plasmids were transformed into yeast and 
cells were serially diluted onto dextrose plates (DUB genes off) and galactose plates (DUB genes 
on) to see whether overexpressing a DUB would cause cell arrest. DUBs UBP10, UBP3, and 
UBP12 appear to arrest cells on the galactose plate compared to the dextrose plate (Figure-9). 
 
 
Figure-9: Over-Expression of UBP10, UBP3, and UBP12 Inhibits Growth. Yeast strains 
containing GST-DUB plasmids were serially diluted 5-fold onto both dextrose (DEX) and 
galactose (GAL) plates. The plasmids are under a GAL1 promoter and therefore the DUB genes 
are only expressed when grown on galactose plates. 
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Next, DUB expression was confirmed in liquid cultures following induction of 
expression by growth in galactose-containing media (see methods). Western blots were 
performed to confirm the DUB plasmid expression worked. A representative GST blot is shown 
below (Figure-10). 
 
 
Figure-10:  GST Western Blot Confirming DUB Over-expression. Yeast strains carrying the 
DUB overexpression plasmids were grown for 2 hours, and then induced with either raffinose 
(Raf) or galactose (Gal) for another 2 hours. Samples were then collected, and Western blots were 
performed with a GST antibody to confirm DUB expression.  
 
Identifying DUBs that Regulate Grr1 Targets 
 After the all of the DUB plasmids had been confirmed for expression and observed for 
potential cell arrest, they were then analyzed to see whether overexpressing each DUB would 
increase the stability of any Grr1 target. This was done by first transforming each of the 11 GST 
plasmids, and an empty vector plasmid, into a target reporter strain YPS2-4 (MATa his31 
ura30 leu20 CLN3-13MYC-HIS3 CLN2-3HA-KanMX PFK27-3FLAG-Hygro), in which the 
Grr1 targets Cln2, Cln3, and Pfk27 were tagged. Expression of DUBs was induced by the 
addition of galactose for 2 hours, samples were collected, and levels of tagged proteins were 
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assayed by Western blotting. My prediction was that overexpression of DUBs that can 
deubiquitinate Grr1 targets blocking their degradation would lead to elevated expression of some 
or all Grr1 targets.  Interestingly, I found that DOA4, UBP3, UBP5, UBP9, and UBP12 
overexpression each resulted in increased Cln2 protein levels (upper panel) (Figure-11). In 
addition, UBP5 overexpression led to accumulation of a higher molecular weight form of Cln2, 
potentially representing the phosphorylated protein. However, a second Grr1 substrate, Cln3 
(second panel), did not appear to increase following overexpression of any DUB. Laddered 
bands appear because Cln3 has many phosphorylated forms. Pfk27-FLAG was not detectable in 
any samples, most likely due to the fact that PFK27 is not transcribed when cells are grown in 
galactose (Benanti et al, 2007) (not shown).   
 
 
Figure-11: Western Blots of Cln2 and Cln3 in Cells Overexpressing GST-DUBs. GST-DUB 
plasmids were each transformed into YPS2-4. Galactose was added to the strains for 2 hours 
allowing for DUB overexpression.  Cells were collected and Western blots performed to compare 
levels of substrate proteins. A GST blot was also performed to verify the plasmids were 
expressing the DUBs when samples were collected. A Cdc28 blot is shown as a loading control. 
 
 25 
 
 Next, the GST plasmids were transformed into the second target reporter strain YPS5-3 
(MATa ura30 leu20 his30 met150 TYE7-3FLAG-Hyg GIC2-3HA-KanMX HOF1-13MYC-
His3MX), in which Gic2, Hof1, and Tye7 were tagged and the experiment carried out as 
described above. I found that cells over-expressing DUBs UBP3 and UBP12 had increased Gic2 
substrate protein levels (Figure-12), while Hof1 levels did not appear to increase significantly. 
Similar to the results for Pfk27, Tye7 was not detectable in any sample, consistent with the fact 
that it is not transcribed when cells are grown in galactose (Benanti et al, 2007) (not shown).  
 
 
 
 
 
Figure-12: Western Blots of GST-DUBs in YPS5-3 Affecting Gic2 and Hof1 Protein 
Substrate Levels. GST-DUB plasmids were each transformed into YPS5-3. Galactose was added 
to the strains for 2 hours allowing for DUB overexpression.  The samples were collected, and then 
Western blots were performed for the tagged substrate proteins to observe their levels. A GST blot 
was also done to verify the plasmids were expressing the DUBs when samples were collected. 
 
 
 Next, the 6 MORF plasmids, along with an empty vector plasmid, were transformed into 
the same 2 target reporter strains, and the experiments were carried out as before.  However, I 
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found that I could not detect expression of any of the Grr1 targets in these strains because the 
MORF tag (which contains a Protein A epitope) cross-reacted with all antibodies. For example, 
an HA blot against Cln2-HA is shown below (Figure-13). As seen by the presence of many 
bands, only the overexpressed MORF-tagged proteins are detectable in the HA-blot. In the 
future, these DUBs will be cloned into a vector without the MORF tag, so that their effect on 
Grr1 substrates can be analyzed. 
 
 
 
Figure-13: Western Blots of Cross-Reacting MORF-DUB Plasmids in YPS2-4. MORF 
plasmids were each transformed into YPS2-4 and galactose induced for 2 hours allowing for DUB 
overexpression. Samples were collected, and then an HA Western blot was performed in order to 
detect Cln2. However, the cross-reactivity of the antibodies with the overexpressed MORF 
proteins prevented the analysis of Cln2 levels. 
 
 
 
 My hypothesis is that overexpression of a DUB that can deubiquitinate a particular Grr1 
target will lead to increased stability of that target.  Since overexpression of 5 GST-DUBs 
resulted in elevated levels of Cln2, this suggests that these DUBs may stabilize Cln2 or other 
Grr1 targets. (Figure-11,-12). To test this, the half-life of Grr1 targets was analyzed following 
overexpression of these DUBs. The same process was repeated as before, except cycloheximide 
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was added to the strains for 1 hour following galactose-induction to inhibit new protein 
synthesis, and samples were taken every 15 min. Levels of each Grr1 target were then followed 
by Western  blot. I found that UBP3 and UBP12 affected Cln2 stability, while UBP12 affects 
Cln3 stability (Figure-14). 
 
 
Figure-14: Half-Life Assay of GST Plasmids in YPS2-4. GST-DUB plasmids in YPS2-4 were 
galactose induced for 2 hours allowing for DUB overexpression. Cycloheximide was then added 
for 1 hour, and 15 minutes samples were taken. Finally, Western blots were performed for tagged 
proteins in order to observe protein stability over time. A GST blot was also done to verify the 
plasmids were expressing the DUBs when samples were collected. Experiment was done by B. 
Landry. 
 
 
In addition, UBP3 and UBP12 affected Gic2 substrate stability (Figure-15). Hof1 
showed stabilization for all proteins, which is most likely due to the MYC tag (not 
shown). 
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Figure-15: Half-Life Assay of GST Plasmids in YPS5-3. GST-DUB plasmids in YPS5-3 were galactose 
induced for 2 hours allowing for DUB overexpression. Cycloheximide was then added for 1 hour, and 15 
min samples were taken. Finally, Western blots were performed for tagged proteins to observe protein 
stability over time. A GST blot was also done to verify the plasmids were expressing the DUBs when 
samples were collected. Experiment was done by B. Landry. 
 
 
Identifying DUBs that Rescue GRR1 Overexpression 
Interestingly, overexpression of GRR1 has been shown to arrest cells, although the 
mechanism of this arrest is unknown. One possibility is that overexpression of Grr1 leads to 
degradation of important substrates, such as G1 cyclins, and cells cannot proceed through the cell 
cycle without these proteins. A second possibility could be that overexpressing Grr1 leads to 
saturation of SCF complexes with only Grr1, and therefore no other F-box proteins would be 
able to bind to the core SCF complex, and therefore the function of these proteins would be 
inhibited.  To test this, I examined the consequence of overexpressing 2 GRR1 mutants that lack 
the functional domains of Grr1 (Figure-16). Plasmids expressing galactose-inducible full-length 
Grr1 or each of 2 mutated Grr1 plasmids, 1 with the F-box deleted (Grr1F), so that it cannot 
bind to the core SCF complex, and 1 with the leucine-rich repeat domain deleted (Grr1L), so 
that it cannot bind to substrates, were transformed into wild type cells (MATa his3 ura3 leu2 
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met15). Cells were then spotted onto both dextrose and galactose plates. I found that only 
overexpression of the full-length Grr1 (figure second row) arrested the cells on galactose plates, 
meaning a fully functional Grr1 protein that can bind both the SCF complex and substrates is 
needed to arrest cells. This suggests that the second possibility is not true, because the Grr1L 
protein can compete with other F-box proteins for binding to the SCF core complex. If the 
competition model were true, overexpression of Grr1L would be expected to kill cells and it did 
not. Therefore, Grr1-mediated growth inhibition is likely due to increased degradation of 
substrates. 
 
 
Figure-16: Spot Assay of Grr1 and Mutant Overexpression Plasmids. GRR1 plasmids 
(pYES2-GST-URA3, pYES2-GRR1-URA3, pYES2, GRR1F-URA3, pYES2-GRR1L-URA3) were 
transformed into wild type cells, and then serially diluted 5-fold onto both dextrose (DEX) and 
galactose (GAL) plates. Grr1F represents a plasmid with Grr1 missing the F-box, and Grr1L 
represents a plasmid with Grr1 missing the LRR domain. The plasmids are under a GAL1 
promoter, therefore the genes are only expressed on GAL plates. 
 
  
Next, I tested whether overexpression of any DUB could rescue the slow-growth 
phenotype observed from overexpressing Grr1 alone. This was done by first cloning GRR1 into a 
different vector with a LEU2 marker, instead of a URA3 marker, since the DUB plasmids all 
carry URA3 markers and both plasmids required different selectable markers. Then the GRR1 
plasmid and each the 17 DUB plasmids (plus a control) were transformed into wild type cells. 
The strains were then serially diluted onto both dextrose and galactose plates, as explained 
previously. The prediction was that only DUBs that deubiquitinate Grr1 targets will show restore 
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normal growth on galactose plates. However, I found that the LEU2-containing GRR1 
overexpression plasmid alone (Figure-17, second row) did not arrest cells like the URA3-
containing plasmid had before (Figure-16). Therefore, no rescue from DUB overexpression 
could be determined.  
 
 
 
 
Figure-17: Spot Assay of GRR1 and DUB Overexpression Plasmids in Wild Type Cells. 
pRS325-GRR1-LEU2, and the indicated DUB plasmids with URA3 markers, or GST control, 
were transformed into wild type cells and serially diluted 5-fold onto dextrose (DEX) and 
galactose (GAL) plates. All genes are transcribed from the GAL1 promoter, therefore the genes 
are turned on when on the GAL plates only. 
 
 
 
 
 
Overall, 17 of the 20 yeast DUBs were analyzed during this project. A list of DUBs 
tested and the preliminary findings (described below) are summarized in Table-I. 
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DUB Name DUB Family 
Plasmid 
Type 
Expression? Cell Arrest? 
Potential 
Targets 
DOA4 
ubiquitin-specific 
protease 
GST Yes No Unknown 
OTU1 octubain protease GST ? No Unknown 
YUH1 
ubiquitin C-terminal 
hydrolase 
GST Yes No Unknown 
UBP3 
ubiquitin-specific 
protease 
GST Yes Yes Cln2, Gic2 
UBP5 
ubiquitin-specific 
protease 
GST Yes No Unknown 
UBP6 
ubiquitin-specific 
protease 
GST Yes No Unknown 
UBP9 
ubiquitin-specific 
protease 
GST Yes No Unknown 
UBP10 
ubiquitin-specific 
protease 
GST Yes Yes Unknown 
UBP11 
ubiquitin-specific 
protease 
GST Yes No Unknown 
UBP12 
ubiquitin-specific 
protease 
GST Yes Yes 
Cln2, Cln3, 
Gic2 
UBP16 
ubiquitin-specific 
protease 
GST ? No Unknown 
OTU2 octubain protease MORF Yes N/A N/A 
UBP1 
ubiquitin-specific 
protease 
MORF Yes N/A N/A 
UBP2 
ubiquitin-specific 
protease 
MORF Yes N/A N/A 
UBP7 
ubiquitin-specific 
protease 
MORF Yes N/A N/A 
UBP13 
ubiquitin-specific 
protease 
MORF Yes N/A N/A 
RPN11 zinc metalloprotease MORF ? N/A N/A 
 
Table-1: Summary of DUB Analysis. Table 1 shows all the DUBs that were analyzed, the families that they 
belong to, and the type of plasmid that the DUB gene was cloned into. Also shown is whether DUB proteins 
were expressed from the plasmids, and if the DUB plasmids could arrest cells. Potential targets are also shown 
highlighted in yellow for a few DUBs that have been found based off Western blots shown later in Results. A 
question mark indicates the protein expression could not be verified, N/A indicates results for the DUB were not 
tested. 
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DISCUSSION 
 
 
 
 This project was successful in identifying candidate yeast DUBs that regulate the 
degradation of Grr1 targets. Overall, 11 DUBs were analyzed to see if overexpression of any of 
these could rescue the Grr1 targets Cln2, Cln3, and Gic2 from degradation. Overexpression of 
six DUBs resulted in increased expression levels of one or more Grr1 targets. These DUBs were 
analyzed further in half-life assays, and UBP12 overexpression was found to stabilize Cln2, Cln3 
and Gic2. In addition, UBP3 overexpression stabilized Cln2 and Gic2.  
 
In vivo Approaches to Identify DUB Targets 
 It has been shown in vitro that DUBs can process ubiquitin precursor proteins, edit 
ubiquitin modifications by rearranging ubiquitin chains, remove chains from posttranslationally 
modified proteins, and rescue ubiquitin conjugates (Komander, et al., 2009). However, very little 
in vivo research has been done to understand the roles that deubiquitinating enzymes have 
preventing protein degradation within the cell and the substrates that they target, even though we 
know that substrate-specific DUBs exist (Popov, et al., 2007). I took two different approaches, 
biochemical and genetic, to try and develop an assay that will allow for DUB substrates to be 
determined in vivo. 
 
Biochemical Approach 
 For the biochemical approach, I overexpressed individual DUB genes and determined if 
they could regulate the levels of established ubiquitin-proteasome substrates in vivo. I focused on 
proteins targeted by the ubiquitin ligase Grr1 because the structure, function, and targets of Grr1 
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are well understood (Johnston, 1999) and the pathways regulating the degradation of Grr1 targets 
have been elucidated. Following DUB overexpression, the stabilities of the tagged Grr1 targets 
were analyzed by Western blots. DUBs that normally deubiquitinate Grr1 targets were expected 
to display an increase in those targets' expression upon overexpression in vivo. Half-life assays 
then followed for any DUBs that affected protein stability. In the end this approach was 
successful in its efforts to identify several candidate DUB substrates. 
 
Genetic Approach 
 Interestingly, Grr1 overexpression arrests cells, which may be due to accelerated 
degradation if its targets. If this is true, this phenotype could be used to screen for DUBs that 
counteract Grr1 function. However, there are two likely possibilities for Grr1 overexpression 
kills cells: either Grr1 overexpression causes excess substrate degradation (ex. G1 cyclins), or its 
over-expression leads to saturation of SCF complexes.  Using a simple spot assay I was able to 
find that the former of the two is most likely correct, as a fully functional Grr1 was needed to 
arrest cells. Therefore, I was interested to know if overexpression of any DUB could prevent this 
arrest. A newly constructed GRR1 overexpression plasmid was transformed into wildtype cells 
along with separate DUB plasmids and then these strains were spotted onto dextrose and 
galactose plates. DUBs that deubiquitinate Grr1 targets were expected to show increased  growth 
on the galactose plates. However, this newly constructed the GRR1 plasmid did not arrest cells, 
so I could not draw any conclusions from these experiments. 
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Future Directions 
 
Biochemical Approach 
 Although my results were encouraging, several technical hurdles prevented a 
comprehensive analysis of all DUBs and Grr1 targets. Since the 6 MORF-DUB plasmids had a 
Protein A epitope, which binds all immunoglobulins, they cross-reacted with the antibodies that 
were added to the Western blots, and so target protein levels were not able to be determined 
(Figure-11). These 6 DUB genes will be cloned into the GST plasmids, along with the final 3 
DUBs that were missing from the plasmid collections, and the effect of their overexpression on 
Grr1 target levels will be determined. Second, I originally attempted to examine the Grr1 targets 
Pfk27 and Tye7, however they were expressed from their endogenous promoters and both 
promoters are not active in galactose so no protein expression was detected. In the future, we are 
going to express these genes from a different, constitutive promoter (ex. TEF1). Finally, I found 
that the target Hof1 was stabilized by the addition of the 13MYC tag (data not shown), so Hof1 
blots were uninformative. 
 After assaying all DUBs and Grr1 targets, we will follow-up with half-life assays as we 
did before using cycloheximide to confirm stabilization over time. In addition, we will perform 
pull-down experiments to confirm the interaction between DUBs and Grr1 targets. 
  
Genetic Approach 
 Although I found that only full-length Grr1 could arrest cells upon overexpression, I was 
not successful in carrying out the DUB screen for technical reasons. The original GRR1 plasmid 
that arrested cells contained a URA3 marker, which was the same marker as the DUB plasmids. 
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Therefore, GRR1 had to be recloned into a plasmid with a different marker, LEU2, so that both 
plasmids could be selected for simultaneously. However, the new GRR1 LEU2 plasmid did not 
arrest cells like the URA3 plasmid (Figure-13,-14). In the future we are going to make examine 
differences between the two plasmids that may account for this discrepancy to see if we can 
confirm the original finding. 
 Our long term goal is to develop a genome-wide screen that will be able to determine all 
in vivo DUB substrates. My preliminary data suggests that overexpression of DUBs can be used 
to identify in vivo targets. Future experiments will focus on adapting this approach to carry out 
genome-wide screens. 
 36 
BIBLIOGRAPHY 
 
Amerik, A. Y., Li, S.-J., & Hochstrasser, M. (2000). Analysis of the Deubiquitinating Enzymes 
of the Yeast Saccharomyces cerevisiae. Journal of Biological Chemistry, Volume: 381, 981-992. 
 
Amerik, A. Y., & Hochstrasser, M. (2004). Mechanism and function of deubiquitinating 
enzymes. Science Direct, Volume: 1695, 189-207. 
 
Anderson, P. (2010, 2-November). Cell Cycles: Interphase, Mitosis, Cytokinesis. Retrieved 
2011, 31-October from SchoolWorkHelper: http://schoolworkhelper.net/2010/11/cell-cycles-
interphase-mitosis-cytokinesis/ 
 
Barral, Y., Jentsch, S., & Mann, C. (1995). G1 cyclin turnover and nutrient uptake are controlled 
by a common pathway in yeast. Genes and Development, Volume: 9, 399-409. 
 
Benanti, J. A., Cheung, S. K., Brady, M. C., & Toczyski, D. P. (2007). A proteomic screen 
reveals SCFGrr1 targets that regulate the glycolytic–gluconeogenic switch. Nature Cell Biology, 
Volume: 9, 1184-1191. 
 
Bentley, N., & Carr, A. (1997). DNA structure-dependent checkpoints in model systems. Biology 
Chemistry, Volume: 378, 1267-1274. 
 
Blacketer, M., Madaule, P., & Myers, A. (1995). Mutational analysis of morphologic 
differentiation in Saccharomyces cerevisiae. Genetics, Volume: 140, 1259-1275. 
 
Blondel, M., Bach, S., Bamps, S., Dobbelaere, J., Wiget, P., Longaretti, C., et al. (2005). 
Degradation of Hof1 by SCF(Grr1) is important for actomyosin contraction during cytokinesis in 
yeast. The EMBO Journal, Volume: 24, 1440-1452. 
 
Carter, J. S. (2010, October). Mitosis. Retrieved 2011, 6-November from Biology at Clermont 
College: http://biology.clc.uc.edu/courses/bio104/mitosis.htm 
 
Chen, C., Seth, A. K., & Aplin, A. E. (2006). Genetic and Expression Abberations of E3 
Ubiquitin Ligases in Human Breast Cancer. Molecular Cancer Research, Volume: 4, 695-707. 
 
Cohen, P., & Tcherpakov, M. (2010). Will the ubiquitin system furnish as many drug targets as 
protein kinases? Cell, Volume: 143, 686-693. 
 
Cooper, G. M. (2000). The Eukaryotic Cell Cycle. In G. M. Cooper, The Cell: A Molecular 
Approach. Sunderland: Sinauer Associates. 
 
Coux, O., Tanaka, K., & Goldberg, A. L. (1996). Structure and Functions of the 20S and 26S 
Proteasomes. Annual Reviews of Biochemistry, Volume: 35, 801-847. 
 
 37 
Cristina, T. (2002). The Cell Cycle and Cancer. Journal of Young Investigators, Volume: 5, 
retrieved 17 November 2011 from http://www.jyi.org/articletools/cite.php?id=466 
 
Deshaies, R. (1999). SCF and Cullin/RING H2-Based Ubiquitin Ligases. Annual Reviews of Cell 
and Developmental Biology, Volume: 15, 435-467. 
 
Flick, J., & Johnston, M. (1991). GRR1 of Saccharomyces cerevisiae is required for glucose 
repression and encodes a protein with leucine-rich repeats. Molecular and Cellular Biology, 
Volume: 11, 5101-5112. 
 
Freire, R., Murguía, J., Tarsounas, M., Lowndes, N., Moens, P., & Jackson, S. (1998). Human 
and mouse homologs of Schizosaccharomyces pombe rad1(+) and Saccharomyces cerevisiae 
RAD17: linkage to checkpoint control and mammalian meiosis. Genes and Development, 
Volume: 12, 2560-2573. 
 
Hanna, J., Hathaway, N., Tone, Y., Crosas, B., Elsasser, S., Kirkpatrick, D., et al. (2006). 
Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. 
Cell, Volume: 127, 99-111. 
 
Hershko, A., & Ciechanover, A. (1998). The Ubiquitin System. Annual Review of Biochemistry, 
Volume: 67, 425-479. 
 
Hussain, S., Zhang, Y., & Galardy, P. (2009). DUBs and cancer: the role of deubiquitinating 
enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle, Volume: 8, 1688-
1697. 
 
Jaquenoud, M., Gulli, M., Peter, K., & Peter, M. (1998). The Cdc42p effector Gic2p is targeted 
for ubiquitin-dependent degradation by the SCFGrr1 complex. The EMBO Journal, Volume: 17, 
5360-5373. 
 
Johnston, M. (1999). Feasting, fasting and fermenting: glucose sensing in yeast and other cells. 
Science Direct, Volume: 15, 29-33. 
 
Johnson, D., & Walker, C. (1999). Cyclins and Cell Cycle Checkpoints. Annual Review of 
Pharmacology and Toxicology, Volume: 39, 295-312. 
 
Kim, J., & Klionsky, D. J. (2000). Autophagy, Cytoplasm-to-Vacuole Targeting Pathway, and 
Pexophagy in Yeast and Mammalian Cells. Annual Reviews of Biochemistry, Volume: 69, 303-
342. 
 
King, K., & Cidlowski, J. (1998). Cell Cycle Regulation and Apoptosis. Annual Review of 
Physiology, Volume: 60, 601-617. 
 
Komander, D., Clague, M., & Urbe, S. (2009). Breaking the chains: structure and function of the 
deubiquitinases. Nature Reviews. Molecular Cell Biology, Volume: 10, 550-563. 
 
 38 
Kouranti, I., McLean, J. R., Feoktistova, A., Liang, P., Johnson, A. E., Roberts-Galbraith, R. H., 
et al. (2010). A Global Census of Fission Yeast Deubiquitinating Enzyme Localization and 
Interaction Networks Reveals Distinct Compartmentalization Profiles and Overlapping Functions 
in Endocytosis and Polarity. PLoS Biology, Volume: 8, 1-21. 
 
Lindqvist, A. (2009). The decision to enter mitosis: feedback and redundancy in the mitotic entry 
network. The Journal of Cell Biology, Volume: 185, 193-202. 
 
Loeb, J., Kerentseva, T., Pan, T., Sepulveda-Becerra, M., & Liu, H. (1999). Saccharomyces 
cerevisiae G1 cyclins are differentially involved in invasive and pseudohyphal growth 
independent of the filamentation mitogen-activated protein kinase pathway. Genetics, Volume: 
153, 1535-1546. 
 
Nakayama, K. I., Nakayama, K. (2006). Ubiquitin Ligases: Cell-Control and Cancer. Nature 
Reviews Cancer, Volume: 6, 369-381. 
 
Nigro, J. M. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature, 
Volume: 342, 705-708. 
 
Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brummelkamp, T. R., Dirac, A. M., Sixma, T. K., 
et al. (2005). A Genomic and Functional Inventory of Deubiquitinating Enzymes. Cell, Volume: 
123, 773-786. 
 
Perego, P., Jimenez, G. S., Gatti, L., Howell, S. B., & Zunino, F. (2000). Yeast Mutants as a 
Model System for Identification of Determinants of Chemosensitivity. Pharmacological 
Reviews, Volume: 52, 477-491. 
 
Petroski, M. D., & Deshaies, R. J. (2005). Function and regulation of cullin–RING ubiquitin 
ligases. Nature Reviews of Molecular Cell Biology, Volume: 6, 9-20. 
 
Popov, N., Herold, S., Llamazares, M., Schulein, C., & Eilers, M. (2007). Fbw7 and Usp28 
Regulate Myc Protein Stability in Response to DNA Damage. Cell Cycle, Volume: 6, 2327-
2331. 
 
Ramakrishna, S., Suresh, B., & Baek, K.-H. (2010). The role of deubiquitinating enzymes in 
apoptosis. Cellular and Molecular Life Sciences, Volume: 68, 15-26. 
 
Sanchez, Y., Wong, C., Thoma, R., Richman, R., Wu, Z., Piwnica-Worms, H., et al. (1997). 
Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk 
regulation through Cdc25. Science, Volume: 277, 1497-1501. 
 
Schaefer, J. B., & Morgan, D. O. (2011). Protein-linked ubiquitin chain structure restricts 
activity of deubiquitinating enzymes. The Journal of Biological Chemistry, Advanced Online 
Copy, 1-19. 
 
 39 
Sowa, M., EJ, B., Gygi, S., & Harper, J. (2009). Defining the human deubiquitinating enzyme 
interaction landscape. Cell, Volume: 138, 389-403. 
 
Spellman, P., Sherlock, G., Zhang, M., Iyer, V., Anders, K., Eisen, M., et al. (1998). 
Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces 
cerevisiae by microarray hybridization. Molecular Biology of the Cell, Volume: 9, 3273-3297. 
 
Ventii, K. H., & Wilkinson, K. D. (2008). Protein partners of deubiquitinating enzymes. 
Biochemical Journal, Volume: 414, 161-175. 
 
Verschuren, E. W. (2004). The cell cycle and how it is steered by Kaposi's sarcoma-associated 
herpesvirus cyclin. Journal of General Virology, Volume: 85, 1347-1361. 
 
Vodermaier, H. C. (2004). APC/C and SCF: Controlling Each Other and the Cell Cycle. Current 
Biology, Volume: 14, R787-R796. 
 
Zagulski, M., Herbert, C., & Rytka, J. (1998). Sequencing and functional analysis of the yeast 
genome. Acta Biochimica Polonica, Volume: 45, 627-643. 
 
